NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...

Indaptus Therapeutics (INDP) provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of ...

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral ...

(RTTNews) - Indaptus Therapeutics, Inc.(INDP), Monday announced the initiation of a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene's PD-1 ...

Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a market cap of $11.65 million, a price-to-earnings ratio of -0.48 and a beta of 1.60.

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a large decrease in short interest in the month of February.As of February 28th, there was short interest totalling ...

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene’s tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...